Key Takeaways
- • Private equity deal value in life sciences declined in 2023 compared to 2022, as economic uncertainty and elevated interest rates pressured deal activity despite continued sector attractiveness for PE investors seeking recession-resistant opportunities.
- • Investor appetite for early-stage therapies and precommercial medical devices has strengthened, signaling a rebalancing after the biotech funding slowdown that characterized recent years.
- • The Inflation Reduction Act's drug negotiation provisions will create broad operational and commercial ripple effects across life sciences services providers, particularly contract research organizations (CROs) and contract development manufacturing organizations (CDMOs).
- • Surging demand for GLP-1 agonists—including Wegovy, Ozempic, Mounjaro, and Zepbound—is driving incremental demand for manufacturing ingredients and specialized services, creating new investment opportunities within the life sciences supply chain.
- • PE success in life sciences increasingly requires operational and commercial excellence alongside scientific expertise, reflecting a maturation of the investment thesis beyond pure innovation plays.
Summary
The life sciences sector remains a strategic focus for private equity investors seeking innovative, recession-resistant businesses, yet 2023 marked a significant moderation in deal activity. According to Bain & Company's 2024 Global Healthcare Private Equity Report, overall life sciences deal value in 2023 failed to maintain the pace established in 2022, reflecting headwinds from economic uncertainty and persistently high interest rates. This slowdown occurs despite the sector's historical resilience: from 2018 through 2022, PE investments into biopharma, life sciences tools, and diagnostics sectors generated approximately 650 global buyout deals.
Within this challenging environment, notable repositioning is underway. Pharma services—encompassing CROs and CDMOs—have maintained relative strength, with deal values exceeding 2022 levels, suggesting investor confidence in outsourced service models. Concurrently, PE investors have begun displaying renewed comfort deploying capital into early-stage therapies and precommercial medical devices, reversing some of the caution that characterized the biotech funding slowdown.
Regulatory and commercial forces are reshaping the investment landscape. The Inflation Reduction Act's drug negotiation provisions carry broad implications for services providers throughout the life sciences ecosystem. Additionally, accelerating investment in cell, gene, and RNA therapies reflects institutional conviction in next-generation modalities, though these areas require substantial operational expertise to navigate manufacturing complexity and regulatory requirements.
The meteoric rise of GLP-1 agonists—including marketed products Wegovy, Ozempic, Mounjaro, and Zepbound—has created discrete supply-chain opportunities. Surging demand for these obesity and diabetes therapeutics is generating incremental need for specialized manufacturing ingredients and enabling services, presenting targeted investment opportunities for PE funds with operational capabilities.
Going forward, PE success in life sciences demands integrated expertise spanning scientific proficiency, operational execution, and commercial acumen. Funds must navigate innovation cycles while simultaneously managing the regulatory complexity and manufacturing sophistication increasingly central to value creation in the sector.
Within this challenging environment, notable repositioning is underway. Pharma services—encompassing CROs and CDMOs—have maintained relative strength, with deal values exceeding 2022 levels, suggesting investor confidence in outsourced service models. Concurrently, PE investors have begun displaying renewed comfort deploying capital into early-stage therapies and precommercial medical devices, reversing some of the caution that characterized the biotech funding slowdown.
Regulatory and commercial forces are reshaping the investment landscape. The Inflation Reduction Act's drug negotiation provisions carry broad implications for services providers throughout the life sciences ecosystem. Additionally, accelerating investment in cell, gene, and RNA therapies reflects institutional conviction in next-generation modalities, though these areas require substantial operational expertise to navigate manufacturing complexity and regulatory requirements.
The meteoric rise of GLP-1 agonists—including marketed products Wegovy, Ozempic, Mounjaro, and Zepbound—has created discrete supply-chain opportunities. Surging demand for these obesity and diabetes therapeutics is generating incremental need for specialized manufacturing ingredients and enabling services, presenting targeted investment opportunities for PE funds with operational capabilities.
Going forward, PE success in life sciences demands integrated expertise spanning scientific proficiency, operational execution, and commercial acumen. Funds must navigate innovation cycles while simultaneously managing the regulatory complexity and manufacturing sophistication increasingly central to value creation in the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.